Trial Profile
Phase IIa Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 6-Month Open Label Follow-Up Period
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2021
Price :
$35
*
At a glance
- Drugs ANAVEX-2-73/donepezil (Primary) ; Blarcamesine (Primary) ; Blarcamesine (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Proof of concept
- Sponsors Anavex Life Sciences
- 16 Mar 2021 According to an Anavex Life Sciences media release, results analyzing gene biomarkers associated improved drug response have been presented in a peer-reviewed publication in the journal of Neuropharmacology.
- 16 Mar 2021 Results analyzing gene biomarkers associated improved drug response presented in an Anavex Life Sciences media release.
- 26 Oct 2018 According to an Anavex Life Sciences media release, 3 year longitudinal data from the study were presented at the 2018 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.